Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This post stays:
I want Stsi and anatabine to be as successful as the next long, but, regarding touts that this is a cure, or that it is only going up from here, such foolish conjecture is irresponsible, counterproductive, and deceptive. It doesn't belong here. Take it over to another Stsi board. It is an insult to the intelligence of people who want to have an honest dialogue.
What exactly is very significant?
I think they are going to have to synthesize a more powerful compound, or combine anatabine with other drugs, treatments, supplements or remedies, to have a chance in biotech development. The stories of anatabine curing all kinds of ailments does not pass the smell test. The science and medical community most certainly wouldn't endorse or put much faith in such claims--it would be naive at best, career suicide at worst. There will be setbacks and progress with the future development, but the key will be the precision and abilities of the scientists, and the vision of mgmnt on how to position their drug/drugs commercially, especially in regards to viable combo/cocktail candidates. The key is synergy.
It's going to be a long road ahead, with lots of bumps, and of course, no guarantees of success. Until then, be sure to eat your fruits and vegetables.
In addition to facts, opinions are an essential component on these forums. They can and should be debated openly.
Does anyone know for sure how many mg of anatabine are in cigrx? I emailed the company and they did not get back to me (strike one for customer service)
Tia
Finally. I'm proud of you. The 50 scientist line sounds good, but that is also quite irrelevant. They are human and need to make a living, just like the rest of us. Now, what points do I need to address?
Regarding the 2nd part of your answer...sounds like a dangerous red flag to me. Don't let me discourage you though...I'm wishing for success just like you. I just refuse to delude myself...
Think about, also, that anatabine is currently accessible. The fact that it is currently available, and is a supplement, may alter the perception of the FDA and their attitude towards the compound. I couldn't imagine an OTC supplement getting a special 'designation', even if deserved, based on that history. Image and perception are very much ingrained in business cultures, for better or worse.
Thanks for your response. Why couldn't they potentially get any of these expedited approvals by targeting inflammation in general? Keep in mind, anatabine is not being touted as a cure. Consider this from the wikipedia FDA Fast Track Development Program page:
Guess I need your help...nothing jumped out at me. Aside from the potential benefits related to the general regulation of chronic inflammation -- of which it may provide symptomatic relief of various conditions -- the only other indication that sticks out is smoking cessation.
So, if you can shed some light on 'why not just anti-inflammatory' (or smoking cessation), please be less evasive.
Could someone explain to me why the first prescription target for anatabine could not simply be as an anti-inflammatory agent?
That is not the bottom line. The financials of the company could crater the shares, even if the supplement is useful in pharmacology. Furthermore, it doesn't have to 'significantly' lower inflammation to be a good development, does it? And do we 'know' it is safe and well tolerated? Up to this point, maybe, but how about 10, 20 years from now? Also, the FDA thought Vioxx was safe enough to approve and market, until serious cardiovascular issues began surfacing years later. Of course, Merck actually withheld damning safety risk data in order to get it approved. Do you think "doctors" were involved in that cover-up? Doctors do make mistakes, have big egos which can cloud their judgement, etc.
Your reasoning leaves a lot to be desired, fwiw.
Ps. The money Mullen is able to raise will be directly at our expense, not his, whether you think he has it figured out or not.
Comment from NAH story:
I too am for STSI. But I am extremely skeptical of many of the stories. For one, they sound very exaggerated. Two, they cannot be verified/validated. Three, they are reported by posters who put up a wall in front of critical yet reasonable opinions.
I am not against anecdotal stories per se, but critical of how and by whom they are presented.
Did you not read the post I was responding to? The story itself was not relevant to my reply. I began reading the anecdotal comments (recommended by Buddha), but it was just like reading many of the pure pumping posts here...verbatim!
Ps. No criticism of you, Buddhahead. Carry on...
So...based on your anecdotal stories, you believe anatabloc is one of the most powerful anti-inflammatories ever found? Hear that Ohibbs? A "preponderance of evidence" in my face. lol
To state that anatabloc is one of the "most powerful anti-inflammatories ever found" is baseless. There is no credible clinical evidence to suggest this. Are there less credible studies that show anti-inflammatory benefit? Yes, it appears there are. It appears, through these less rigorous studies, to regulate inflammation. That is positive. But does that make it one of the "most powerful" ever found? Hardly.
If you took all the developed drugs (NSAID's, steroids, statins, TNF inhibitors), and all the natural known anti-inflammatories (turmeric, cayenne pepper, pomegranate, marijuana, ginger, garlic, green tea, etc.), and ran parallel studies to compare anti-inflammatory effects, and anatabine came out ahead of the pack or in the top tier, then I could get behind an ambitious statement like that.
Because of the grandiosity of that statement, and the lack of comparable evidence, I'm inclined to think it is arrogant and baseless, respectively. Call it a personal attack if you wish (administrators), but I'll call it common sense.
As far as the safety profile...so far so good. Fwiw, tobacco had a good safety profile for many decades also. I think, however, that because it (anatabine) has been in the food chain for awhile -- without any serious adverse reactions that we know of -- it probably will maintain a good profile. Part of this is probably attributable to it's modest efficacy profile. Incidentally, if it was more "powerful", there would be a greater likelihood of increased side effects on other functions or organs.
As far as "preponderance of evidence" is concerned...when the pharma industry begins to show some interest, or supplement sales skyrocket, or pharma grade clinical results are produced, or more influential institutions get behind the science with considerable capital (Roskamp/Mullen is only a start, and the follow through, as yet, has been very disappointing), then I may buy your argument. Until then, your preponderance position is simply preposterous.
The 'anecdotes' are exactly what we don't need (any more of) on this board: they've been told ad nauseum.
South Florida researchers investigate if diabetes drug can prevent Alzheimer's
http://www.sun-sentinel.com/health/fl-alzheimers-drug-cleveland-trial-20140502,0,3192997.story
Takeda Pharmaceutical Co., based in Japan, is one of the manufacturers of the diabetes drug Actos, being tested for preventing Alzheimer's disease. (ARND WIEGMANN / REUTERS / April 8, 2014)
By Diane C. Lade, Staff writer
8:12 p.m. EDT, May 2, 2014
Is one of the most common chronic medical conditions among seniors connected to one of the most feared?
South Florida researchers have joined a worldwide clinical trial investigating whether a well-known medication for Type 2 diabetes could delay or prevent Alzheimer's disease, an incurable neurological condition affecting almost a half-million Floridians.
As part of what's called the TOMORROW study, Cleveland Clinic in Weston is looking to enroll 120 participants, ages 65 to 83, without any serious medical conditions including diabetes or Alzheimer's.
Research has been showing such a strong connection between the two conditions that some scientists are calling Alzheimer's "Type 3 diabetes," said Dr. H. Murray Todd, medical director of the Memory Disorder Center at Broward Health North in Deerfield Beach.
That means Type 2 diabetics, or those who are not dependent on insulin injections, could be much more likely to end up with Alzheimer's, Todd said.
"Two disorders that seem very dissimilar may, in the long scheme of things, turn out to be very similar in terms of what is going on in the brain," Todd said.
Type 2 diabetes is common among seniors, with 27 percent of U.S. residents older than 65 having the disease and another 13 percent being pre-diabetic, said Dr. Kenneth Burke, board director for the American Diabetes Association chapter in Fort Lauderdale. Yet many patients and their doctors probably aren't aware of the elevated Alzheimer's risk, Burke said.
While good diet, exercise and medication can allow most diabetics to live normal lives, "there is not much yet we can do about the advance of Alzheimer's," Burke said.
What makes the new TOMORROW clinical trial at Cleveland Clinic unique is that it will follow healthy seniors instead of those already diagnosed with Alzheimer's, said study co-investigator Dr. Po-Heng Tsai.
"Most of the [Alzheimer's] studies and treatments so far have focused on disease modification," he said. "There hasn't been much on prevention."
All candidates will undergo a genetic blood test to determine whether they have the TOMM40 and APOE genes. Research has shown APOE carriers are predisposed to Alzheimer's, and scientists suspect TOMM40 also may be a biomarker.
The double-blind trial will enroll seniors with and without the genes but will not disclose who tested positive to either participants or physicians. Some enrollees will be given the Type 2 diabetes medication Actos, others a placebo. All will be tracked up to five years.
The goal: to see whether, among genetically high-risk seniors, those who take Actos are less likely to develop Alzheimer's, or show symptoms later, than those on the placebo, Tsai said. The study also will examine if TOMM40 indeed is a predictor for Alzheimer's.
Actos came under the scrutiny of the Food and Drug Administration in 2010, following reports that the medication might be associated with bladder cancer in men. At the time, the FDA called for a 10-year study of the medication, to see if it posed a cancer risk, but did not withdraw Actos from the market.
Federal investigators also noted that the cancer reports involved patients who had the highest cumulative doses of Actos, with some having taken the drug for years.
Dr. Jeffrey Cummings, director of Cleveland Clinic's Lou Ruvo Center for Brain Health in Las Vegas, said TOMORROW study participants will take only a .8-milligram dose daily, much lower than the standard diabetic treatment, which will keep them at safe cumulative dose levels.
There currently are just a few FDA approved drugs for Alzheimer's, mostly cholinesterase inhibitors like Aricept, and they are prescribed after symptoms appear. Most work for only a short time or not at all, Tsai said, and do nothing to stop the disease's progress.
Scientists stumbled on off-label Alzheimer's treatment possibilities for pioglitazone, also called AD-4833 and the active ingredient in Actos, when previous clinical and animal studies suggested its anti-inflammatory properties might protect the brain.
Exactly why diabetes and Alzheimer's could be connected still isn't known, Broward Health North's Todd said. It may be partly because Type 2 diabetes affects the way the brain uses glucose (or blood sugar) and insulin, a hormone that helps blood sugar move into cells. Scans have shown Alzheimer's patients' brains also don't properly metabolize glucose.
The TOMORROW study, a phase III trial that will enroll about 5,800 people at 50 facilities worldwide, is financed through Actos partners Takeda Pharmaceuticals and Zinfandel Pharmaceuticals.
Multiple lawsuits have been filed against pharmaceutical manufacturers regarding Actos, alleging patients developed bladder cancer after using the drug. Last month, a jury in a Louisiana federal court ordered Takeda and Eli Lilly & Co. to pay a combined $9 billion in punitive damages, finding that the companies had hidden Actos' cancer risk, according to Bloomberg News.
The companies have said they will appeal the ruling, one of the largest levied in the United States against a drug manufacturer for improper handling of a product.
dlade@tribune.com or 954-356-4295954-356-4295
Interested?
To participate in the TOMORROW study, call Cleveland Clinic in Weston at 954-659-6428
There were over a dozen posts discussing this article, which materialized well over a week ago. It started with #msg-100261274.
Just letting you know, in case you were on vacation.
(This is not OT!)
Even if you are correct about this -- which at this point seems unlikely and suspect (thus irresponsible and misleading on your behalf) -- for all intents and purposes, he is still being paid.
Ps. You did say stock or options earlier in the thread:
I am more inclined to believe that over this. Can you blame me? Be honest...
Free money!
Not that it makes much of a difference, but feel free to provide some documentation on the compensation arrangement.